Hereditary Angioedema clinical trials at UCSD

3 in progress, 1 open to eligible people

Showing trials for

  • STAR-0215 in Participants With Hereditary Angioedema

    open to eligible people ages 18 years and up

    The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

    San Diego, California and other locations

  • Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

    Sorry, in progress, not accepting new patients

    This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

    San Diego, California and other locations

  • HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

    Sorry, in progress, not accepting new patients

    This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

    San Diego, California and other locations

Last updated: